These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 25217422)

  • 1. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study.
    Fossati N; Trinh QD; Sammon J; Sood A; Larcher A; Sun M; Karakiewicz P; Guazzoni G; Montorsi F; Briganti A; Menon M; Abdollah F
    Eur Urol; 2015 Jan; 67(1):3-6. PubMed ID: 25217422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
    Culp SH; Schellhammer PF; Williams MB
    Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local Therapy Improves Survival in Metastatic Prostate Cancer.
    Leyh-Bannurah SR; Gazdovich S; Budäus L; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Steuber T; Huland H; Graefen M; Karakiewicz PI
    Eur Urol; 2017 Jul; 72(1):118-124. PubMed ID: 28385454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis.
    Löppenberg B; Dalela D; Karabon P; Sood A; Sammon JD; Meyer CP; Sun M; Noldus J; Peabody JO; Trinh QD; Menon M; Abdollah F
    Eur Urol; 2017 Jul; 72(1):14-19. PubMed ID: 27174537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.
    Pompe RS; Tilki D; Preisser F; Leyh-Bannurah SR; Bandini M; Marchioni M; Gild P; Tian Z; Fossati N; Cindolo L; Shariat SF; Huland H; Graefen M; Briganti A; Karakiewicz PI
    Prostate; 2018 Jul; 78(10):753-757. PubMed ID: 29663462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.
    Mazzone E; Preisser F; Nazzani S; Tian Z; Bandini M; Gandaglia G; Fossati N; Montorsi F; Graefen M; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    Eur Urol Oncol; 2019 Sep; 2(5):541-548. PubMed ID: 31411992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.
    Gandaglia G; Sun M; Trinh QD; Becker A; Schiffmann J; Hu JC; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI; Abdollah F
    BJU Int; 2014 Dec; 114(6b):E62-E69. PubMed ID: 24467651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Gandaglia G; Boorjian SA; Parker WP; Zaffuto E; Fossati N; Bandini M; Dell'Oglio P; Suardi N; Montorsi F; Karnes RJ; Briganti A
    Eur Urol; 2017 Dec; 72(6):910-917. PubMed ID: 28622831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
    Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
    J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival and cancer-specific survival were improved in local treatment of metastatic prostate cancer.
    Miao Q; Wei Z; Liu C; Ye Y; Cheng G; Song Z; Chen K; Zhang Y; Chen J; Yue C; Ruan H; Zhang X
    Front Oncol; 2023; 13():1130680. PubMed ID: 37207146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis.
    Moschini M; Morlacco A; Kwon E; Rangel LJ; Karnes RJ
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):117-121. PubMed ID: 28045114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis.
    Abdollah F; Suardi N; Cozzarini C; Gallina A; Capitanio U; Bianchi M; Sun M; Fossati N; Passoni NM; Fiorino C; Di Muzio N; Karakiewicz PI; Rigatti P; Montorsi F; Briganti A
    Eur Urol; 2013 Jun; 63(6):998-1008. PubMed ID: 23122664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting survival of patients with node-positive prostate cancer following multimodal treatment.
    Abdollah F; Karnes RJ; Suardi N; Cozzarini C; Gandaglia G; Fossati N; Bianchi M; Boorjian SA; Sun M; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol; 2014 Mar; 65(3):554-62. PubMed ID: 24094576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis.
    Sheng W; Kirschner-Hermanns R; Zhang H
    World J Urol; 2019 Feb; 37(2):317-325. PubMed ID: 29951790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis.
    Bandini M; Pompe RS; Marchioni M; Tian Z; Gandaglia G; Fossati N; Tilki D; Graefen M; Montorsi F; Shariat SF; Briganti A; Saad F; Karakiewicz PI
    World J Urol; 2018 Jan; 36(1):7-13. PubMed ID: 29063268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer.
    Abdollah F; Gandaglia G; Suardi N; Capitanio U; Salonia A; Nini A; Moschini M; Sun M; Karakiewicz PI; Shariat SF; Montorsi F; Briganti A
    Eur Urol; 2015 Feb; 67(2):212-9. PubMed ID: 24882672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Might definitive local therapy of the primary tumor improve the survival benefits of metastatic prostate cancer?-evidence from a meta-analysis.
    Xiao M; Cong R; Zhang Q; Xiang W; Xiao H
    Ann Palliat Med; 2020 May; 9(3):648-660. PubMed ID: 32312070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival Outcomes for Metastatic Prostate Cancer Patients Treated With Radical Prostatectomy or Radiation Therapy: A SEER-based Study.
    Jin K; Qiu S; Jin H; Zheng X; Zhou X; Jin D; Li J; Yang L; Wei Q
    Clin Genitourin Cancer; 2020 Dec; 18(6):e705-e722. PubMed ID: 32763123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.